HOME >> BIOLOGY >> NEWS
New MS research shows remarkable findings

Montreal, February 5, 2004 - New research findings from the Research Institute of the McGill University Health Center (MUHC) provide hope for patients with multiple sclerosis (MS), one of the most common and devastating diseases of the nervous system. These findings, published in today in Neuron, characterize an enzyme that plays a central role in the onset and progress of MS.

" We have identified a key enzyme that triggers MS-like disease in an animal model," says MUHC neuroscientist and Professor of Medicine at McGill University, Dr. Sam David. "We also show that blocking this enzyme has a remarkable effect in preventing disease and relapses."

MS, an autoimmune disease of the nervous system, affects approximately 35,000 young adults in Canada. It is twice as prevalent in females. MS is an inflammatory disease in which the body's own immune system attacks the insulating membranes surrounding nerve fibers. This damage results in loss of sensations and paralysis. Although genetic, infectious or environmental factors are thought to induce MS, the exact cause of the disease is still not known.

Dr. David with his Ph.D. student Athena Kalyvas showed in a mouse model of MS that the amount of the enzyme, phospholipase A2 (cPLA2), is increased in spinal cord lesions. They further demonstrated that treatment with a chemical inhibitor of this enzyme results in a marked reduction in the onset and severity of the disease.

"This discovery suggests that the cPLA2 enzyme may be an excellent target for the development of drugs to treat MS, " concluded Dr. David.


'"/>

Contact: Christine Zeindler
christine.zeindler@muhc.mcgill.ca
514-934-1934
McGill University
5-Feb-2004


Page: 1

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
4. Belgian researchers explore revolutionary approach to angiogenesis
5. Award winning researchers reveal potential new role for Glivec
6. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
7. 16 APS exercise research highlights, from reduced flu mortality to proteomics & obesity
8. Gene chips research in cotton could lead to superior variety
9. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
10. New hydrothermal vents discovered as South Pacific Odyssey research begins
11. University of Alberta researcher looks for clues to mysterious disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/22/2019)... ... October 21, 2019 , ... Join QPS experts ... Bioanalytical in a live session on Thursday, October 31, 2019 at 11am ... , A good CRO partner should have expertise in method development, which can be ...
(Date:10/22/2019)... ... ... Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group ... with German biotech strategy consulting firm, Catenion. The seminar will take place from 16:00 ... , Speakers from Greenberg Traurig and Catenion will discuss best practices and practical tips ...
(Date:10/19/2019)... ... October 18, 2019 , ... Scientists from ... and experience the best their field has to offer. PI engineers are on-hand ... industry and research. , Micro- and Nanopositioning Stages for Linear and Rotary Motion, ...
Breaking Biology News(10 mins):
(Date:10/17/2019)... OVERLAND PARK, Kan. (PRWEB) , ... October 15, ... ... rating to 23andMe, a leader among services that offer DNA Testing for health ... become so popular. Everywhere you look, it seems that people want to know ...
(Date:10/10/2019)... ... October 09, 2019 , ... The ... Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker for the 2019 ... Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and palliative medicine physician, is ...
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial ... research centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial ... and certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials ...
(Date:10/8/2019)... BOSTON (PRWEB) , ... October 08, 2019 , ... Today, ... U.K. of its lead development technology. Like the company’s precursor patent, approved in ... and accurate counting of tissue stem cells. Asymmetrex now markets the technology in ...
Breaking Biology Technology:
Cached News: